Clinical and Echocardiographic Parameters Predicting 1- and 2-Year Mortality After Transcatheter Aortic Valve Implantation

Background: Transcatheter aortic valve implantation (TAVI) has become a standard treatment option for patients with symptomatic aortic stenosis. Elderly high-risk patients treated with TAVI have a high residual mortality due to preexisting comorbidities. Knowledge of factors predicting futility afte...

Full description

Bibliographic Details
Published in:Frontiers in Cardiovascular Medicine
Main Authors: Didrik Kjønås, Henrik Schirmer, Svend Aakhus, Jo Eidet, Siri Malm, Lars Aaberge, Rolf Busund, Assami Rösner
Format: Article in Journal/Newspaper
Language:English
Published: Frontiers Media S.A. 2021
Subjects:
Online Access:https://doi.org/10.3389/fcvm.2021.739710
https://doaj.org/article/00df49095fcc470395835826ecb7b4d2
id ftdoajarticles:oai:doaj.org/article:00df49095fcc470395835826ecb7b4d2
record_format openpolar
spelling ftdoajarticles:oai:doaj.org/article:00df49095fcc470395835826ecb7b4d2 2023-05-15T17:39:25+02:00 Clinical and Echocardiographic Parameters Predicting 1- and 2-Year Mortality After Transcatheter Aortic Valve Implantation Didrik Kjønås Henrik Schirmer Svend Aakhus Jo Eidet Siri Malm Lars Aaberge Rolf Busund Assami Rösner 2021-12-01T00:00:00Z https://doi.org/10.3389/fcvm.2021.739710 https://doaj.org/article/00df49095fcc470395835826ecb7b4d2 EN eng Frontiers Media S.A. https://www.frontiersin.org/articles/10.3389/fcvm.2021.739710/full https://doaj.org/toc/2297-055X 2297-055X doi:10.3389/fcvm.2021.739710 https://doaj.org/article/00df49095fcc470395835826ecb7b4d2 Frontiers in Cardiovascular Medicine, Vol 8 (2021) TAVI mortality echocardiography strain risk assessment Diseases of the circulatory (Cardiovascular) system RC666-701 article 2021 ftdoajarticles https://doi.org/10.3389/fcvm.2021.739710 2022-12-31T07:24:47Z Background: Transcatheter aortic valve implantation (TAVI) has become a standard treatment option for patients with symptomatic aortic stenosis. Elderly high-risk patients treated with TAVI have a high residual mortality due to preexisting comorbidities. Knowledge of factors predicting futility after TAVI is sparse and clinical tools to aid the preoperative evaluation are lacking. The aim of this study was to evaluate if echocardiographic measures, including speckle-tracking analysis, in addition to clinical parameters, could aid in the prediction of mortality beyond 30 days after TAVI.Methods: This prospective observational cohort study included 227 patients treated with TAVI at the University Hospital of North Norway, Tromsø and Oslo University Hospital, Rikshospitalet from February 2010 to June 2013. All the patients underwent preoperative echocardiographic evaluation with retrospective speckle-tracking analysis. Primary endpoints were 1- and 2-year mortality beyond 30 days after TAVI.Results: All-cause 1- and 2-year mortality beyond 30 days after TAVI was 12.1 and 19.5%, respectively. Predictors of 1-year mortality beyond 30 days were body mass index [hazard ratio (HR): 0.88, 95% CI: 0.80–0.98, p = 0.018], previous myocardial infarction (HR: 2.69, 95% CI: 1.14–6.32, p = 0.023), and systolic pulmonary artery pressure ≥ 60 mm Hg (HR: 5.93, 95% CI: 1.67–21.1, p = 0.006). Moderate-to-severe mitral regurgitation (HR: 2.93, 95% CI: 1.53–5.63, p = 0.001), estimated glomerular filtration rate (HR: 0.98, 95% CI: 0.96–0.99, p = 0.002), and chronic obstructive pulmonary disease (HR: 1.9, 95% CI: 1.01–3.58, p = 0.046) were predictors of 2-year mortality.Conclusion: Both the clinical and echocardiographic parameters should be considered when evaluating high-risk patients for TAVI, as both are predictive of 1-and 2-year mortality. Our results support the importance of individual risk assessment using a multidisciplinary, multimodal, and individual approach. Article in Journal/Newspaper North Norway Tromsø Directory of Open Access Journals: DOAJ Articles Norway Tromsø Frontiers in Cardiovascular Medicine 8
institution Open Polar
collection Directory of Open Access Journals: DOAJ Articles
op_collection_id ftdoajarticles
language English
topic TAVI
mortality
echocardiography
strain
risk assessment
Diseases of the circulatory (Cardiovascular) system
RC666-701
spellingShingle TAVI
mortality
echocardiography
strain
risk assessment
Diseases of the circulatory (Cardiovascular) system
RC666-701
Didrik Kjønås
Henrik Schirmer
Svend Aakhus
Jo Eidet
Siri Malm
Lars Aaberge
Rolf Busund
Assami Rösner
Clinical and Echocardiographic Parameters Predicting 1- and 2-Year Mortality After Transcatheter Aortic Valve Implantation
topic_facet TAVI
mortality
echocardiography
strain
risk assessment
Diseases of the circulatory (Cardiovascular) system
RC666-701
description Background: Transcatheter aortic valve implantation (TAVI) has become a standard treatment option for patients with symptomatic aortic stenosis. Elderly high-risk patients treated with TAVI have a high residual mortality due to preexisting comorbidities. Knowledge of factors predicting futility after TAVI is sparse and clinical tools to aid the preoperative evaluation are lacking. The aim of this study was to evaluate if echocardiographic measures, including speckle-tracking analysis, in addition to clinical parameters, could aid in the prediction of mortality beyond 30 days after TAVI.Methods: This prospective observational cohort study included 227 patients treated with TAVI at the University Hospital of North Norway, Tromsø and Oslo University Hospital, Rikshospitalet from February 2010 to June 2013. All the patients underwent preoperative echocardiographic evaluation with retrospective speckle-tracking analysis. Primary endpoints were 1- and 2-year mortality beyond 30 days after TAVI.Results: All-cause 1- and 2-year mortality beyond 30 days after TAVI was 12.1 and 19.5%, respectively. Predictors of 1-year mortality beyond 30 days were body mass index [hazard ratio (HR): 0.88, 95% CI: 0.80–0.98, p = 0.018], previous myocardial infarction (HR: 2.69, 95% CI: 1.14–6.32, p = 0.023), and systolic pulmonary artery pressure ≥ 60 mm Hg (HR: 5.93, 95% CI: 1.67–21.1, p = 0.006). Moderate-to-severe mitral regurgitation (HR: 2.93, 95% CI: 1.53–5.63, p = 0.001), estimated glomerular filtration rate (HR: 0.98, 95% CI: 0.96–0.99, p = 0.002), and chronic obstructive pulmonary disease (HR: 1.9, 95% CI: 1.01–3.58, p = 0.046) were predictors of 2-year mortality.Conclusion: Both the clinical and echocardiographic parameters should be considered when evaluating high-risk patients for TAVI, as both are predictive of 1-and 2-year mortality. Our results support the importance of individual risk assessment using a multidisciplinary, multimodal, and individual approach.
format Article in Journal/Newspaper
author Didrik Kjønås
Henrik Schirmer
Svend Aakhus
Jo Eidet
Siri Malm
Lars Aaberge
Rolf Busund
Assami Rösner
author_facet Didrik Kjønås
Henrik Schirmer
Svend Aakhus
Jo Eidet
Siri Malm
Lars Aaberge
Rolf Busund
Assami Rösner
author_sort Didrik Kjønås
title Clinical and Echocardiographic Parameters Predicting 1- and 2-Year Mortality After Transcatheter Aortic Valve Implantation
title_short Clinical and Echocardiographic Parameters Predicting 1- and 2-Year Mortality After Transcatheter Aortic Valve Implantation
title_full Clinical and Echocardiographic Parameters Predicting 1- and 2-Year Mortality After Transcatheter Aortic Valve Implantation
title_fullStr Clinical and Echocardiographic Parameters Predicting 1- and 2-Year Mortality After Transcatheter Aortic Valve Implantation
title_full_unstemmed Clinical and Echocardiographic Parameters Predicting 1- and 2-Year Mortality After Transcatheter Aortic Valve Implantation
title_sort clinical and echocardiographic parameters predicting 1- and 2-year mortality after transcatheter aortic valve implantation
publisher Frontiers Media S.A.
publishDate 2021
url https://doi.org/10.3389/fcvm.2021.739710
https://doaj.org/article/00df49095fcc470395835826ecb7b4d2
geographic Norway
Tromsø
geographic_facet Norway
Tromsø
genre North Norway
Tromsø
genre_facet North Norway
Tromsø
op_source Frontiers in Cardiovascular Medicine, Vol 8 (2021)
op_relation https://www.frontiersin.org/articles/10.3389/fcvm.2021.739710/full
https://doaj.org/toc/2297-055X
2297-055X
doi:10.3389/fcvm.2021.739710
https://doaj.org/article/00df49095fcc470395835826ecb7b4d2
op_doi https://doi.org/10.3389/fcvm.2021.739710
container_title Frontiers in Cardiovascular Medicine
container_volume 8
_version_ 1766140175629418496